Literature DB >> 6449339

Suppression of DNA synthesis by con A-activated human lymphocytes: role of monocytes in con A-induced suppression.

C G Kallenberg, G C de Gast, T H The.   

Abstract

Human peripheral blood mononuclear leucocytes, activated by Con A, suppress the antigen- or mitogen-induced proliferation of autologous responder cells. Generation of suppressor cells is prevented by mitomycin treatment before Con A activation. Once cells are activated, their suppressive activity is not affected by mitomycin treatment. Monocytes are not only required for generation of suppressor cells, but are also involved in suppression as effector cells. Monocyte-mediated suppression is blocked by indomethacin, suggesting that this suppression is mediated by prostaglandin. It is concluded that monocytes are involved in Con A-induced suppression of DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6449339      PMCID: PMC1537031     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

Review 1.  Separation and functional analysis of subpopulations of lymphocytes bearing complement and Fc receptors.

Authors:  C R Parish
Journal:  Transplant Rev       Date:  1975

2.  Concanavalin A-activated suppressor cells in normal human peripheral blood lymphocytes.

Authors:  C Hubert; G Delespesse; A Govaerts
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

3.  Human suppressor T cells induced by concanavalin A: suppressor T cells belong to distinctive T cell subclasses.

Authors:  T Sakane; I Green
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

4.  Activation of human B lymphocytes. III. Concanavalin A-induced generation of suppressor cells of the plaque-forming cell response of normal human B lymphocytes.

Authors:  B F Haynes; A S Fauci
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

5.  Prostaglandin-producing suppressor cells in Hodgkin's disease.

Authors:  J S Goodwin; R P Messner; A D Bankhurst; G T Peake; J H Saiki; R C Williams
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

6.  Circulating suppressor cells in man as a function of age.

Authors:  J P Antel; M Weinrich; B G Arnason
Journal:  Clin Immunol Immunopathol       Date:  1978-01

7.  Suppression of DNA synthesis by Con A-activated human lymphocytes: Stimulation by con A bound to non-T cells unless removed after activation.

Authors:  G C De Gast; T H The; E Ponds; C Kallenberg
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

8.  Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors.

Authors:  L Shou; S A Schwartz; R A Good
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

9.  Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T cells bearing receptors for IgM or IgG.

Authors:  L Moretta; S R Webb; C E Grossi; P M Lydyard; M D Cooper
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

10.  Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell.

Authors:  J S Goodwin; A D Bankhurst; R P Messner
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

View more
  3 in total

1.  Modifying the biological response in acute myeloid leukemia. II. Effect of BCG and leukemic cells on lymphocyte response to mitogens, and on helper and suppressor activity.

Authors:  A Arends-Merino; R Giscombe; C Ogier; P Reizenstein; A M Sjörgen; J Wasserman
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

2.  Relative ability to provide help: an explanation for Con A-induced suppression.

Authors:  J Farrant; C Newton
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

Review 3.  Macrophages: progress and problems.

Authors:  D S Nelson
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.